| KrasG12D-driven proliferation of pancreatic ductal epithelial cells (PDECs) depends on an EGFR signaling loop engaging the oncogenic transcription factor c-MYC. | pancreatic, |
| Glucocorticoid effect on oncogene/growth gene expression in human T lymphoblastic leukemic cell line CCRF-CEM. Specific c-myc mRNA suppression by dexamethasone. | leukemia, |
| [Immunohistochemical study of c-myc oncogene product in human brain tumors]. | brain, |
| c-myc oncogene product expression and prognosis in operable breast cancer. | breast, |
| [Expression of c-myc oncogene product and its relation to cell cycle in human gastric cancers]. | gastric, |
| Proliferation of the human colon carcinoma cell line HT29: autocrine growth and deregulated expression of the c-myc oncogene. | colorectal, |
| Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. | HNSC, |
| While TP53 mutation and MYC amplification were synergistic in promoting tumor progression, PIK3CA mutation was found to have alleviated the oncogenic effect of either the TP53 mutation or MYC amplification, and was associated with a significant reduction in mitotic activity in TP53 mutated and/or MYC amplified breast cancer | breast, |
| Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. | colorectal, |
| Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene-driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression. | lymphoma, |
| Hypomethylation of c-myc proto-oncogene of N-nitrosomorpholine--induced rat liver nodules and of H4IIE cells. | liver, |
| Results indicate that spliceosome inhibitors would be promising molecular target drugs in small cell lung cancer (SCLC) irrespective of the myc proto-oncogene protein (MYC) status. | lung, |
| Mechanism of activation and biological role of the c-myc oncogene in B-cell lymphomagenesis. | lymphoma, |
| N-myc oncogene expression in histopathologically unrelated bilateral pediatric renal tumors. | pediatric,kidney, |
| Sequence analysis of the MYC oncogene involved in the t(8;14)(q24;q11) chromosome translocation in a human leukemia T-cell line indicates that putative regulatory regions are not altered. | leukemia, |
| Transgenic rabbits with lymphocytic leukemia induced by the c-myc oncogene fused with the immunoglobulin heavy chain enhancer. | leukemia, |
| Novel combination of c-myc, N-myc and N-ras oncogene alteration in brain tumors. | brain, |
| Cooperation between the polyomavirus middle-T-antigen gene and the human c-myc oncogene in a rat thyroid epithelial differentiated cell line: model of in vitro progression. | thyroid, |
| Data suggest that, in breast cancer cells, MYC acts as an upstream regulator leading to PGK1 activation. (MYC, proto-oncogene c-myc; PGK1, phosphoglycerate kinase 1) | breast, |
| Control of c-fos and c-myc proto-oncogene induction in rat thyroid cells in culture. | thyroid, |